Platelets and Atherothrombosis: An Essential Role for Inflammation in Vascular Disease — A Review

[1]  J. Farmer Reversal of atherosclerosis with aggressive lipid lowering. , 2005, Current atherosclerosis reports.

[2]  E. Tuzcu,et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease , 2005 .

[3]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[4]  S. Devaraj,et al.  C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis? , 2004, Hypertension.

[5]  D. Newby,et al.  Upregulation of the CD40/CD40 Ligand Dyad and Platelet-Monocyte Aggregation in Cigarette Smokers , 2004, Circulation.

[6]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[7]  G. Cagney,et al.  Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. , 2004, Blood.

[8]  P. Burger,et al.  Platelets in Inflammation and Thrombosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[9]  J. Kaski,et al.  The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. , 2003, Journal of the American College of Cardiology.

[10]  E. Topol,et al.  Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.

[11]  H. Bae,et al.  Serial Measurement of Surface Expressions of CD63, P-Selectin and CD40 Ligand on Platelets in Atherosclerotic Ischemic Stroke , 2003, Cerebrovascular Diseases.

[12]  W. Koenig,et al.  Utility of inflammatory markers in the management of coronary artery disease. , 2003, The American journal of cardiology.

[13]  M. Hori,et al.  Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. , 2003, Atherosclerosis.

[14]  K. Newby,et al.  C‐Reactive Protein: A Novel Marker of Cardiovascular Risk , 2003, Cardiology in review.

[15]  Petr Jarolim,et al.  Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones , 2003, Circulation.

[16]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[17]  M. Gawaz,et al.  Engagement of Glycoprotein IIb/IIIa (&agr;IIb&bgr;3) on Platelets Upregulates CD40L and Triggers CD40L-Dependent Matrix Degradation by Endothelial Cells , 2002, Circulation.

[18]  Patrick André,et al.  Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. , 2002, Circulation.

[19]  F. Cambien,et al.  Interleukin-18 Is a Strong Predictor of Cardiovascular Death in Stable and Unstable Angina , 2002, Circulation.

[20]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[21]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[22]  L. Drouet Atherothrombosis as a Systemic Disease , 2002, Cerebrovascular Diseases.

[23]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[24]  P. Libby,et al.  CD40 Signaling and Plaque Instability , 2001, Circulation research.

[25]  P. Ridker,et al.  Novel clinical markers of vascular wall inflammation. , 2001, Circulation research.

[26]  Deepak L. Bhatt,et al.  Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. , 2001, The American journal of cardiology.

[27]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[28]  P. Mcgeer,et al.  Generation of C-reactive protein and complement components in atherosclerotic plaques. , 2001, The American journal of pathology.

[29]  P. Ridker,et al.  Soluble P-Selectin and the Risk of Future Cardiovascular Events , 2001, Circulation.

[30]  K. Schrör,et al.  Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel , 2001, Platelets.

[31]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[32]  M. Daemen,et al.  Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Libby,et al.  Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Banchereau,et al.  CD40‐CD40 ligand , 2000, Journal of leukocyte biology.

[35]  P. Ridker,et al.  Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. , 1999, The American journal of cardiology.

[36]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[37]  P. Ridker,et al.  Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. , 1998, Circulation.

[38]  J. Finkelstein,et al.  Disruption of the CD40-CD40 ligand system prevents an oxygen-induced respiratory distress syndrome. , 1998, The American journal of pathology.

[39]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[40]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[41]  R. D'Agostino,et al.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.

[42]  C. Visser,et al.  C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. , 1997, Circulation.

[43]  V. Fuster,et al.  Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.

[44]  A. Aruffo,et al.  Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. , 1993, Science.

[45]  G. Lozanski,et al.  Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. , 1992, Cytokine.

[46]  D. Symmons,et al.  Cause of death in rheumatoid arthritis. , 1984, British journal of rheumatology.

[47]  Eric J. Topol,et al.  Scientific and therapeutic advances in antiplatelet therapy , 2003, Nature Reviews Drug Discovery.

[48]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.